To destroy infectious agents, the immune system creates \u201cspecific\u201d antibodies against the antigens that pathogens express. At the time of infection, \u201cspecific\u201d antibodies are only present if a previous vaccination against the infectious agent has been received.<\/p>\n
Before \u201cspecific\u201d antibodies are produced, pathogens can be joined by antibodies that are naturally present in the individual (for example, those of blood groups), or that have been previously produced against other infectious agents.<\/p>\n
The problem is that most of these \u201cnon-specific\u201d antibodies do not have destructive capacity against the new pathogen. On the contrary, in many cases these \u201cnon-specific\u201d antibodies can create a shield that prevents the immune system from acting, despite the production of \u201cspecific\u201d antibodies against them.<\/p>\n
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB) discovered that the elimination of \u201cnon-specific\u201d antibodies that bind to gram-negative bacteria with a new drug allows the immune system to respond against these bacteria, preventing them from causing diseases, as presented in the scientific journal Frontiers in Immunology.<\/p>\n
Gram-negative bacteria are most responsible for infections acquired within hospitals, particularly in the ICU, many of them being resistant to antibiotics, and there are no vaccines available to prevent them.<\/p>\n
The development of new treatments against these bacteria is a priority objective for public health, as indicated by the World Health Organization (WHO), the US Center for Disease Control (CDC) and the European Commission. \u201cIt is the first time that it has been shown that immunity can be generated against infections by eliminating existing antibodies, without the need to produce new ones as vaccines do, which can be of great help to prevent infections like those acquired in hospitals\u201d – points out Dr. Rafael Ma\u00f1ez, head of the IDIBELL research group and head of the Intensive Medicine Service at the HUB.<\/p>\n
RemAb Therapeutics designed a platform of polymeric conjugates using HART technology (Harmful Antibody Removal Technology) from which they generated drugs that for the first time eliminate antibodies from the human body.<\/p>\n
The first drug developed by RemAb Therapeutics is RA0127, which eliminates \u201cnon-specific\u201d antibodies that facilitate infections caused by gram-negative bacteria. After confirming the effectiveness and safety of the new drug in various preclinical investigations, the Spanish Agency for Medicines and Health Products (AEMPS) authorized the initiation of clinical trials with the new drug.<\/p>\n
The drug is a \u201cFirst-in-class-drug<\/em>\u201d that uses a new and unique mechanism of action to prevent hospital-acquired infections.<\/p>\n","protected":false},"excerpt":{"rendered":" The new treatment is a drug that eliminates the antibodies that bind to gram-negative bacteria and makes them resistant to destruction by the immune system.<\/p>\n","protected":false},"author":8,"featured_media":23099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-25 02:23:49","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23098"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=23098"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23098\/revisions"}],"predecessor-version":[{"id":23100,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/23098\/revisions\/23100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media\/23099"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=23098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/categories?post=23098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/tags?post=23098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}